408P Proxalutamide plus endocrine therapy as a combination therapy in women with HR+/HER2-/AR+ metastatic breast cancer: A phase I study

• DOI: 10.1016/j.annonc.2023.09.585
• Publication Date: 2023-10-20T11:34:24Z
• Authors: H. Li; H. Jiang; G. Song; R. Ran; J. Wang; X. Wang; J. Huang; J. Feng; L. Zhang; A. Zang; H. Yang; Y. Pan; X. He; M. Donng; Y. Tong; Z. Wang; Z. Shao
• Keywords: Fulvestrant; Tolerability; Letrozole; Combination therapy; Exemestane; Palbociclib; Mucositis